Dexamethasone (DEX), a corticosteroid, is an essential component of antiemetic regimens recommended by several guidelines, including ASCO, European
We aimed to compare the antiemetic efficacy of ondansetron and dexamethasone combination with that of the use of each agent alone to decrease the incidence of post
We designed this study to investigate the direct antiemetic action of dexamethasone in the
People with cancer undergoing chemotherapy are given this medication to lessen nausea and vomiting
Long-term steroid use increases blood glucose level in both diabetic and non
It has been used as an antiemetic in patients receiving chemotherapy for more than three decades and was first studied in surgical patients in the early nineties 1
All three guidelines recom-mend the use of dexamethasone for the acute prevention of highly, moderately, and low emetogenic Intramuscular dexamethasone injections are painful and can be difficult to administer, so oral administration is a preferred route, especially owing to a suggested 80% bioavailability
dexamethasone (DexPak Dexamethasone is an effective antiemetic drug, but its mechanism of action is unclear
In the next cycle of chemotherapy, the
Aprepitant should be considered, although evidence to support its use specifically in these patients is lacking
Surprisingly, there have been no well-controlled studies of cannabinoids in the era of combination antiemetic therapy with 5-HT3 receptor antagonists plus dexamethasone
15 mg/kg IV
Open‑label dexamethasone was also given as part of the antiemetic treatment with a dosage regimen dependent on whether the chemotherapy regimen was moderately or highly emetogenic (12 mg on day 1 for
Aprepitant should be considered although evidence to support its use specifically in these patients is lacking